원격전이가 발생한 폐경전 여성 유방암 환자에서의 예후인자
Prognostic Factors for Premenopausal Women with Distant Metastatic Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Several studies have reported that the survival after distant metastasis in younger patients with breast cancer was similar to that in elderly patients. Moreover, few studies have observed better survival outcome after distant metastasis in younger patients with breast cancer. Here, we have identified the factors that affect the prognosis after distant metastasis in these patients. Methods: We reviewed 7,157 patients that underwent primary breast cancer surgery between January 2003 and December 2013 at the Samsung Medical Center. Three hundred and thirty two premenopausal patients aged <50 years showed distant metastasis and were included in the analysis. For further analysis, the patients older or younger than 40 years were divided into 2 groups. Results: There were no demographic differences in the patient characteristics such as clinical stage, nuclear grade, lymphovascular invasion, distant metastasis site, distant metastasis free interval (DMFI), except the estrogen receptor (ER) and progesterone receptor (PR) statuses, histopathology, and molecular subtype in both the groups (p-value=0.023, 0.035, 0.016, 0.046, respectively). The median follow-up period was 79.4 months. Next, we did not observe significant difference in the overall survival (OS) between the two groups (Log rank p-value=0.975). However, patients in the luminal A and luminal B group showed better OS than those in human epidermal growth factor receptor-2 (HER-2) positive, and triple-negative breast cancer (TNBC) group (Log-rank p-value<0.001). Furthermore, patients showed worse OS when they developed distant metastases within 36 months post-surgery (Log-rank p-value<0.001). In overall, age did not affect the survival outcome (p-value=0.547); however, the molecular subtype, DMFI, and distant metastasis sites showed significant differences in the patient outcome (p-value<0.001, respectively). Conclusion: Our analysis suggests that the molecular subtype, DMFI, and distant metastasis site serve as useful predictors for prognosis in younger breast cancer patients with distant metastasis. However, age in these patients did not correlate well with mortality.
Abstract
Purpose: Several studies have reported that the survival after distant metastasis in younger patients with breast cancer was similar to that in elderly patients. Moreover, few studies have observed better survival outcome after distant metastasis in younger patients with breast cancer. Here, we have identified the factors that affect the prognosis after distant metastasis in these patients. Methods: We reviewed 7,157 patients that underwent primary breast cancer surgery between January 2003 and December 2013 at the Samsung Medical Center. Three hundred and thirty two premenopausal patients aged <50 years showed distant metastasis and were included in the analysis. For further analysis, the patients older or younger than 40 years were divided into 2 groups. Results: There were no demographic differences in the patient characteristics such as clinical stage, nuclear grade, lymphovascular invasion, distant metastasis site, distant metastasis free interval (DMFI), except the estrogen receptor (ER) and progesterone receptor (PR) statuses, histopathology, and molecular subtype in both the groups (p-value=0.023, 0.035, 0.016, 0.046, respectively). The median follow-up period was 79.4 months. Next, we did not observe significant difference in the overall survival (OS) between the two groups (Log rank p-value=0.975). However, patients in the luminal A and luminal B group showed better OS than those in human epidermal growth factor receptor-2 (HER-2) positive, and triple-negative breast cancer (TNBC) group (Log-rank p-value<0.001). Furthermore, patients showed worse OS when they developed distant metastases within 36 months post-surgery (Log-rank p-value<0.001). In overall, age did not affect the survival outcome (p-value=0.547); however, the molecular subtype, DMFI, and distant metastasis sites showed significant differences in the patient outcome (p-value<0.001, respectively). Conclusion: Our analysis suggests that the molecular subtype, DMFI, and distant metastasis site serve as useful predictors for prognosis in younger breast cancer patients with distant metastasis. However, age in these patients did not correlate well with mortality.
참고문헌 (26)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Parkin DM, "International variation", Oncogene, 23, pp.6329~6340 (2004)
- Leong SP, "Is breast cancer the same disease in Asian and Western countries?", World J Surg, 34, pp.2308~2324 (2010)
- Han W, "Young age : an independent risk factor for disease-free survival in women with operable breast cancer", BMC Cancer, 4, pp.82~ (2004)
- Han JG, "Clinicopathologic characteristics and prognosis of young patients with breast cancer", Breast, 20, pp.370~372 (2011)
- Anders CK, "Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression", J Clin Oncol, 26, pp.3324~3330 (2008)
- Gnerlich JL, "Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease", J Am Coll Surg, 208, pp.341~347 (2009)
- Dubsky PC, "Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer", Clin Breast Cancer, 3, pp.65~72 (2002)
- Purushotham A, "Age at diagnosis and distant metastasis in breast cancer – a surprising inverse relationship", Eur J Cancer, 50, pp.1697~1705 (2014)
- Zhenchong Xiong, "Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model", Cancer Research and Treatment, 50(4), pp.1260~1269 (2018), 대한암학회
- Lee ES, "Identifying the potential long-term survivors among breast cancer patients with distant metastasis", Ann Oncol, 27, pp.828~833 (2016)
- Chen MT, "Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups : a SEER population-based analysis", Sci Rep, 7, pp.9254~ (2017)
- Kao KJ, "Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes : implications for treatment optimization", BMC Cancer, 11, pp.143~ (2011)
- Kataoka A, "Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors : a study from the Japanese breast cancer registry", Breast Cancer Res Treat, 160, pp.163~172 (2016)
- Brandt J, "Age at diagnosis in relation to survival following breast cancer : a cohort study", World J Surg Oncol, 13, pp.33~ (2015)
- Zhang X, "Young age is an independent adverse prognostic factor in early stage breast cancer : a population-based study", Cancer Manag Res, 10, pp.4005~4018 (2018)
- Bakkach J, "Clinicopathologic and prognostic features of breast cancer in young women : a series from North of Morocco", BMC Womens Health, 17, pp.106~ (2017)
- Tjokrowidjaja A, "Metastatic breast cancer in young women : a population-based cohort study to describe risk and prognosis", Intern Med J, 44, pp.764~770 (2014)
- Largillier R, "Prognostic factors in 1, 038 women with metastatic breast cancer", Ann Oncol, 19, pp.2012~2019 (2008)
- Yoo TK, "Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery", Breast Cancer Res Treat, 165, pp.109~118 (2017)
- Chang E, "Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival : findings from the SEER database", Breast Cancer Res Treat, 173, pp.209~216 (2019)
- 김희준, "Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse", Journal of Breast Cancer, 18(4), pp.371~377 (2015), 한국유방암학회
- Lobbezoo DJ, "Prognosis of metastatic breast cancer subtypes : the hormone receptor", HER2-positive subtype is associated with the most favorable outcome, 2013, pp.141, 507~514
- Xiao W, "Breast cancer subtypes and the risk of distant metastasis at initial diagnosis : a population-based study", Cancer Manag Res, 10, pp.5329~5338 (2018)
- Gong Y, "Impact of molecular subtypes on metastatic breast cancer patients : a SEER population-based study", Sci Rep, 7, pp.45411~ (2017)
- Di Leo A, "Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors : a critical assessment based on recently reported phase III trials in colorectal and breast cancer", J Clin Oncol, 21, pp.2045~2047 (2003)